Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of HP-3150 (diclofenac sodium transdermal) in Shoulder Periarthritis, Cervico-omo-brachial Syndrome and Tenosynovitis
jRCT2080225041Phase 3Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diclofenac in Periarthritis humeroscapularis, Cervicobrachialgia and tendovaginitis (2 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoint: Change in pain VAS score at week 2. Started Jan 2020; status: completed.
02
Drugs
diclofenac
03
Conditions
Periarthritis humeroscapularisCervicobrachialgiatendovaginitis
Beyond the preview
Go deeper on jRCT2080225041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225041.